Financhill
Buy
60

LIVN Quote, Financials, Valuation and Earnings

Last price:
$63.96
Seasonality move :
9.24%
Day range:
$62.56 - $64.18
52-week range:
$32.48 - $64.31
Dividend yield:
0%
P/E ratio:
38.16x
P/S ratio:
2.59x
P/B ratio:
3.02x
Volume:
496K
Avg. volume:
643.4K
1-year change:
24.83%
Market cap:
$3.5B
Revenue:
$1.3B
EPS (TTM):
-$4.01

Analysts' Opinion

  • Consensus Rating
    LivaNova Plc has received a consensus rating of Buy. The company's average rating is a Buy based on 5 Buy ratings, 2 Hold ratings, and 0 Sell ratings.
  • Price Target Upside
    According to analysts' consensus price target of $69.10, LivaNova Plc has an estimated upside of 8.14% from its current price of $63.90.
  • Price Target Downside
    According to analysts, the lowest downside price target is $56.00 representing 100% downside risk from its current price of $63.90.

Fair Value

  • According to the consensus of 7 analysts, LivaNova Plc has 8.14% upside to fair value with a price target of $69.10 per share.

LIVN vs. S&P 500

  • Over the past 5 trading days, LivaNova Plc has underperformed the S&P 500 by -0.02% suggesting its relative strength compared to the major market average is weak at this time.

Share Buyback

  • LivaNova Plc does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.

Revenue Growth

  • LivaNova Plc has grown year-over-year revenues for 12 quarters straight. In the most recent quarter LivaNova Plc reported revenues of $357.8M.

Earnings Growth

  • LivaNova Plc earnings have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter LivaNova Plc reported earnings per share of $0.49.
Enterprise value:
3.3B
EV / Invested capital:
2.03x
Price / LTM sales:
2.59x
EV / EBIT:
16.93x
EV / Revenue:
2.47x
PEG ratio (5yr expected):
-0.01x
EV / Free cash flow:
17.39x
Price / Operating cash flow:
18.27x
Enterprise value / EBITDA:
12.66x
Gross Profit (TTM):
$923.9M
Return On Assets:
-8.6%
Net Income Margin (TTM):
-16.12%
Return On Equity:
-18.29%
Return On Invested Capital:
-12.15%
Operating Margin:
15.83%
Trailing 12 Months Fiscal Quarters
Period Ending 2023-09-30 2024-09-30 2025-09-30 2024-09-30 2025-09-30
Income Statement
Revenue $1.1B $1.2B $1.3B $318.1M $357.8M
Gross Profit $766M $843.7M $923.9M $225.3M $244.9M
Operating Income $82.5M $137.3M -$164.7M $44.8M $56.6M
EBITDA $142.7M $191.7M -$107.2M $57.9M $71.8M
Diluted EPS $0.05 $0.43 -$4.01 $0.60 $0.49
Period Ending 2021-09-30 2022-09-30 2023-09-30 2024-09-30 2025-09-30
Balance Sheet
Current Assets $646.4M $851.2M $953.9M $1.1B $1.1B
Total Assets $2.2B $2.2B $2.3B $2.5B $2.6B
Current Liabilities $658.5M $288M $295.4M $324.4M $827.6M
Total Liabilities $890.9M $1.1B $1.1B $1.2B $1.4B
Total Equity $1.3B $1.1B $1.2B $1.3B $1.2B
Total Debt $273.1M $565.2M $612.4M $670.3M $477.5M
Trailing 12 Months Fiscal Quarters
Period Ending 2023-09-30 2024-09-30 2025-09-30 2024-09-30 2025-09-30
Cash Flow Statement
Cash Flow Operations $39.7M $158.3M $250.7M $51M $85.1M
Cash From Investing -$39.1M -$49.6M -$53.4M -$18.5M -$23.1M
Cash From Financing $24.8M $17M -$226.2M -$3.3M -$9.4M
Free Cash Flow $8.5M $108.7M $191.4M $32.8M $62.2M
LIVN
Sector
Market Cap
$3.5B
$28.8M
Price % of 52-Week High
99.36%
51.13%
Dividend Yield
0%
0%
Shareholder Yield
1.71%
-1.32%
1-Year Price Total Return
24.83%
-20.64%
Beta (5-Year)
1.020
0.520
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years

Technicals

8-day SMA
Buy
Level $63.18
200-day SMA
Buy
Level $47.26
Bollinger Bands (100)
Buy
Level 47.61 - 58.21
Chaikin Money Flow
Buy
Level 75.1M
20-day SMA
Buy
Level $57.32
Relative Strength Index (RSI14)
Buy
Level 71.39
ADX Line
Buy
Level 29.49
Williams %R
Sell
Level -3.4338
50-day SMA
Buy
Level $54.72
MACD (12, 26)
Buy
Level 2.86
25-day Aroon Oscillator
Buy
Level 68
On Balance Volume
Neutral
Level 133.9M

Financial Scores

Hold
Altman Z-Score (Annual)
Level (1.8385)
Buy
CA Score (Annual)
Level (0.157)
Buy
Beneish M-Score (Annual)
Level (-2.797)
Buy
Momentum Score
Level (5)
Buy
Ohlson Score
Level (-0.918)
Buy
Piotroski F Score (Annual)
Level (7)
Buy
Quality Ratio Score
Level (8)
Buy
Fundamental Score
Level (4)

Revenue Forecast

Earnings per Share Forecast

Company Profile

LivaNova Plc is a global medical technology company, which engages in the development and delivery of therapeutic solutions for the benefit of patients, healthcare professionals, and healthcare systems. It operates through the following segments: Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support (ACS). The Cardiopulmonary segment is involved in the design, development, manufacture, marketing and selling of cardiopulmonary products. The Neuromodulation segment is associated in the design, development, manufacture, marketing and selling of devices that deliver neuromodulation therapy for treating DRE and DTD. The ACS segment deals with the design, development, manufacture, marketing and selling of temporary life support products. The company was founded in 1987 and is headquartered in London, the United Kingdom.

Stock Forecast FAQ

In the current month, LIVN has received 5 Buy ratings 2 Hold ratings, and 0 Sell ratings. The LIVN average analyst price target in the past 3 months is $69.10.

  • Where Will LivaNova Plc Stock Be In 1 Year?

    According to analysts, the consensus estimate is that LivaNova Plc share price will rise to $69.10 per share over the next 12 months.

  • What Do Analysts Say About LivaNova Plc?

    Analysts are divided on their view about LivaNova Plc share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that LivaNova Plc is a Sell and believe this share price will drop from its current level to $56.00.

  • What Is LivaNova Plc's Price Target?

    The price target for LivaNova Plc over the next 1-year time period is forecast to be $69.10 according to 7 Wall Street analysts, 5 of them rate the stock a Buy, 0 rate the stock a Sell, and 2 analysts rate the stock a Hold.

  • Is LIVN A Buy, Sell Or Hold?

    According to Wall Street analysts, the consensus rating for LivaNova Plc is a Buy. 5 of 7 analysts rate the stock a Buy at this time.

  • How Can I Buy Shares Of LIVN?

    You can purchase shares of LivaNova Plc via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase LivaNova Plc shares.

  • What Is The LivaNova Plc Share Price Today?

    LivaNova Plc was last trading at $63.96 per share. This represents the most recent stock quote for LivaNova Plc. Yesterday, LivaNova Plc closed at $63.90 per share.

  • How To Buy LivaNova Plc Stock Online?

    In order to purchase LivaNova Plc stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Is Amazon an AI Stock?
Is Amazon an AI Stock?

With the market starting to look skittish on pure-play AI…

Google Vs NVIDIA Stock: Which Is Best?
Google Vs NVIDIA Stock: Which Is Best?

Alphabet (NASDAQ:GOOGL) and NVIDIA (NASDAQ:NVIDIA) are two of the market’s…

How High Could NVIDIA Stock Go?
How High Could NVIDIA Stock Go?

NVIDIA (NASDAQ:NVDA) has been one of the best stocks to…

Stock Ideas

Buy
52
Is NVDA Stock a Buy?

Market Cap: $4.5T
P/E Ratio: 62x

Buy
61
Is AAPL Stock a Buy?

Market Cap: $4.1T
P/E Ratio: 38x

Buy
63
Is GOOG Stock a Buy?

Market Cap: $3.8T
P/E Ratio: 40x

Alerts

Buy
54
SMX alert for Dec 5

SMX (Security Matters) Plc [SMX] is up 130.5% over the past day.

Sell
15
HOV alert for Dec 5

Hovnanian Enterprises, Inc. [HOV] is down 0.63% over the past day.

Buy
67
NUTX alert for Dec 5

Nutex Health, Inc. [NUTX] is up 1.29% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock